Inhibitors of viral entry are under consideration as topical microbicides to prevent HIV-1 sexual transmission. Small molecules targeting HIV-1 gp120 (BMS-378806) or CCR5 (CMPD167), and a peptide fusion inhibitor (C52L), each blocks vaginal infection of macaques by a SHIV. A microbicide, however, must be active against multiple HIV-1 variants. We therefore tested BMS-C (a BMS-378806 derivative), CMPD167, C52L and the CXCR4 ligand AMD3465, alone and in combination, against 25 primary R5, 12 X4 and 7 R5X4 isolates from subtypes A-G. At high concentrations (0.1-1 μM), the replication of most R5 isolates in human donor lymphocytes was inhibited by > 90%. At lower concentrations, double and triple combinations were more effective than individual inhibitors. Similar results were obtained with X4 viruses when AMD3465 was substituted for CMPD167. The R5X4 viruses were inhibited by combining AMD3465 with CMPD167, or by the coreceptor-independent compounds. Thus, combining entry inhibitors may improve microbicide effectiveness.
Introduction
In the continuing absence of an effective vaccine, the use of a topical microbicide represents a credible alternative method to reduce the sexual transmission of human immunodeficiency virus type 1 (HIV-1). The microbicide concept remains to be validated, in that no compounds have yet been shown to prevent HIV-1 transmission in efficacy trials (Dhawan and Mayer, 2006; Klasse et al., 2006; Lee et al., 2003; Shattock and Moore, 2003) . Several efficacy trials of early generation microbicide candidates, mostly polyanion-based, are due to be completed in the next few years. Provided these microbicides are used regularly, it is possible that one or more of them will show significant efficacy, although trials of one polyanion, cellulose sulphate, were recently abandoned due to an increased rate of infections in the active arm. If the other polyanions are also found not to be protective, the focus will fall on the next generation of microbicide candidates that are in pre-clinical development or early-stage clinical trials (Dhawan and Mayer, 2006; Lederman et al., 2006; Shattock and Moore, 2003) .
Among such next-generation concepts are entry inhibitors, compounds that inhibit the fusion of HIV-1 with its target cells by specifically interfering with virus-receptor interactions or the subsequent stages of the entry process. Several different entry inhibitors have now been shown to be effective at preventing SHIV infection of macaques by the vaginal and/or rectal routes (Dhawan and Mayer, 2006; Klasse et al., 2006; Lederman et al., 2006) . One significant problem that will need to be overcome by an entry-inhibitor-based microbicide, indeed by any microbicide, is the global sequence diversity of HIV-1 (McCutchan, 2006; Walker and Korber, 2001) . As is now well appreciated, HIV-1 is an extraordinarily variable virus, its diversity exceeding other viral pathogens' by orders of magnitude. This factor affects the design and performance of HIV-1 vaccines, and it is just as relevant an issue for microbicide development; any product that could prevent the transmission of only a small subset of the viruses its users encountered would not be of much practical value.
The breadth of protection against diverse HIV-1 strains cannot be readily gauged in the macaque model, because only a very few SHIVs are available for microbicide testing Lederman et al., 2006) . Tissue-culture studies must, therefore, suffice. It is possible to assess the breadth of reactivity of vaccine-induced antibodies or neutralizing monoclonal antibodies (MAbs) in vitro by measuring their ability to inhibit the infection of target cells by viruses from multiple different genetic subtypes (Binley et al., 2004; Brown et al., 2005; Burton et al., 2004; Li et al., 2005; Moore and Burton, 2004) . A neutralizing antibody is, of course, an entry inhibitor, one that works by binding to the viral envelope glycoproteins (Burton et al., 2000; Klasse and Sattentau, 2002 ). Hence the same or similar virus test panels used for neutralization studies can be used to gauge the breadth of activity of candidate microbicides in vitro.
We have, therefore, assembled a multi-subtype HIV-1 test panel and used it to study a selection of different entry inhibitors, including compounds we have previously shown to be effective at preventing SHIV infection of macaques after vaginal challenge (Veazey et al., 2005) . The test compounds are the small-molecule CCR5 inhibitor CMPD167, the gp120binding attachment inhibitor BMS-C, the gp41-targeted fusion inhibitory peptide C52L, and the small-molecule CXCR4 inhibitor AMD3465. We have tested each of these inhibitors as individual agents, and we have also evaluated their performance in pair-wise and triple combinations. The rationale for testing inhibitor combinations is that the use of several compounds with different, complementary mechanisms of action is one possible answer to the problems posed by HIV-1 diversity (Veazey et al., 2005) . The chances of a virus being simultaneously resistant to three compounds is obviously less than to any single inhibitor, a principle well established from clinical experience with drug-based therapies for HIV-1 infection (Yeni et al., 2004) . Furthermore, the combination of CXCR4-and CCR5-specific inhibitors may be useful for countering the transmission of dual-tropic viruses since, although X4 viruses are rarely transmitted, this can occur (Dhawan and Mayer, 2006; Gupta and Klasse, 2006; Klasse et al., 2006; Margolis and Shattock, 2006; .
Results

Entry inhibitor microbicide candidates and virus test panels
We have previously shown that the small-molecule CCR5 inhibitor CMPD167, the gp120-binding small-molecule attachment inhibitor BMS-378806 and the gp41-peptide fusion inhibitor C52L, alone and in combination, can protect rhesus macaques against infection by the R5 virus SHIV-162P3 when used as vaginal microbicides (Veazey et al., 2005) . BMS-C is a member of the same structural family of compounds as BMS-378806 but has greater potency in vitro, so we selected it for further study. AMD3465 is a small-molecule inhibitor that binds to CXCR4 (Hatse et al., 2005) . We are now evaluating it in the macaque model for protection against the vaginal transmission of viruses that use CXCR4 for entry into primary cells in vitro.
In the present study, we have explored the activities of each of these compounds against HIV-1 primary isolates from different genetic subtypes in vitro, to gain insights into their practical utility as topical microbicides. Based on the known properties of these inhibitors, CMPD167 should only be active against R5 viruses and AMD3465 only against X4 viruses, whereas the inhibitory effects of BMS-C and C52L should be coreceptor-independent (Guo et al., 2003; Matthews et al., 2004) . Some of the test viruses were derived from a test panel put together for evaluating the breadth of activity of vaccineinduced neutralizing antibodies (Brown et al., 2005) . Others were isolated from individuals in the relatively early stages of infection, so might be representative of viruses that expand in the new host post-transmission (Rusert et al., 2005) .
The test viruses were grouped by coreceptor usage: R5, X4 or dual-tropic (R5 + X4 or R5X4). In total, we used 25 R5 viruses, 12 X4 viruses and 7 dual-tropic viruses, from 7 genetic subtypes or circulating recombinant forms (CRFs) ( Table 1) . We placed more emphasis on the R5 virus test panel because viruses with this phenotype are the most commonly transmitted successfully (Lederman et al., 2006; . However, although X4 viruses are rarely transmitted, it is possible that a microbicide might have to counter viruses of this phenotype, particularly if the transmitter has been infected for several years, allowing the evolution of CXCR4-using strains (Dhawan and Mayer, 2006; Gupta and Klasse, 2006; Margolis and Shattock, 2006; . Isolates that use only CXCR4 are rare compared to ones that contain mixtures of viruses with either phenotype (R5 + X4) and/or clonal viruses that can use both coreceptors (R5X4) (Brumme et al., 2005; Moyle et al., 2005) . A caveat is that the most commonly used assays for viral phenotype are based on cell lines such as U87/CD4-CCR5 and U87/CD4-CXCR4 (Brumme et al., 2005; Moyle et al., 2005) , and coreceptor usage patterns on cell lines and on primary cells are not always correlated (Yi et al., 2005; Zhang and Moore, 1999; Zhang et al., 1998) . We therefore tested the entry inhibitors only against dual-tropic isolates that we had confirmed could use both CCR5 and CXCR4 to enter primary CD4 + T-cells, by showing that they were sensitive to a combination of the CCR5-specific inhibitor CMPD167 with a CXCR4-specific inhibitor (AMD3465 or AMD3100) (Zhang and Moore, 1999; Zhang et al., 1998) (and data not shown). These isolates probably contain mixtures of R5 and X4 viruses and, perhaps, also genuinely dual-tropic viruses able to use either coreceptor.
Evaluation of entry inhibitors, alone and in combination, against primary isolates from multiple genetic subtypes Each inhibitor was initially tested against each virus in a PBMC-based replication assay at four different concentrations that were separated by a factor of 10. This strategy enabled us to gain an insight into how sensitive each virus was without determining formal IC 50 values, which would be logistically infeasible given the number of viruses and inhibitors involved in the study. We selected 90% inhibition of p24 production as a marker for definitive, high-level activity of a compound against a test virus (see Methods). At the highest tested concentration, 1 μM, C52L inhibited all viruses by > 90% (Table 2 ). This degree of potency is compatible with its reported range of IC 90 values, 20-200 nM, against eight viruses (Deng et al., 2007) , six of which were re-tested here, and also with its reported IC 50 values against HIV-1 BaL and SHIV-162P3 (Veazey et al., 2005) . BMS-C at 1 μM inhibited all the R5X4 viruses by > 90%, but only 84% of the R5 and 58% of the X4 viruses. A 1 nM concentration of CMPD167 was sufficient to inhibit all the R5 viruses by > 90%, while a 5 μM concentration of AMD3465 was required for a similar degree of inhibition of all the X4 viruses (at this concentration, some non-specific effects of AMD3465 became apparent). Thus single inhibitors showed substantial breadth of activity against the current panel of viruses, albeit at different concentration ranges.
We then sought to identify the concentration of each inhibitor that would be active at this level (> 90% inhibition) against a substantial subset (∼ 50%) of the test viruses, so that we could assess whether combining different inhibitors increased the breadth of coverage against the test panel as a whole. Our intention was not to determine whether different inhibitors could act additively or synergistically; to do that would require complex titrations of each inhibitor, alone and in pairs, against each virus, which is not practical in a study on this scale (a more narrowly focused study of synergy is now in progress). Instead, we tried to ascertain whether any viruses would be resistant to intermediate concentrations of two or more inhibitors. Obviously, the use of any one inhibitor at a concentration that was, itself, sufficient to inhibit almost all the test viruses would not allow us to determine whether adding a second inhibitor could now suppress the remaining viruses. Ideally, the hit-rate for each individual compound across the entire test panel would be ∼ 20-50% at the most suitable concentration, but given the diversity of the viruses in the test panel, and virus-dependent variation in inhibitor potency, it was not always possible to achieve this goal (Figs. 1-3; Table 2) .
When tested at low, sub-optimal concentrations, each of CMPD167 (0.1 nM), BMS-C (1 nM) and C52L (1 nM) inhibited only a subset (0-16%) of the 25 R5 viruses by 90%, but the breadth of coverage was increased by the use of two or three inhibitors together (Table 2A) . For example, CMPD167 alone inhibited only 8% of the viruses at this low concentration, BMS-C only 16%, but the two together were active against 56% of the panel. By itself, at the 1 nM concentration, C52L inhibited none of the test viruses by 90%, but its presence increased the breadth of coverage conferred by either CMPD167 or BMS-C, and the triple inhibitor combination was active against 68% of the viruses in the panel (Table 2A) . When the concentration of each individual inhibitor was increased by 10-fold, CMPD167 (1 nM) now inhibited 100% of the test viruses, demonstrating its substantial breadth of activity against R5 viruses, but preventing any assessment of the effect of combining it with other inhibitors. However, the combination of BMS-C (10 nM) with C52L (10 nM) was more broadly active than either inhibitor was by itself (80% coverage compared to 68% and 4% for the two inhibitors added alone; Table 2A ).
A similar finding was made with the X4 virus test panel. Thus, AMD3465 (5 nM) inhibited 17% of the viruses and BMS-C (1 nM) also inhibited 17%, but 58% of the viruses were sensitive to the two compounds added together. The addition of C52L (1 nM) did not increase the frequency of inhibition (the marginal decreases were insignificant; Fisher's exact test, P > 0.5). At higher concentrations (50 nM AMD3465, 10 nM BMS-C and 10 nM C52L), the individual compounds inhibited part of the test panel (8-75%), but the breadth of coverage was again improved by the use of combinations (75-92% inhibition; Table 2B ). When dual-tropic viruses were tested, the benefits of inhibitor combinations were again sometimes observable; for example, at the higher concentration of 50 nM AMD3465 and 1 nM CMPD167, each compound alone inhibited only 14% of the viruses, whereas the combination was active against 100% (Table 2C ). This is an expected finding in a multi-cycle replication assay: any dual-tropic virus that can use a coreceptor that is not blocked will be able to amplify during the course of the culture, overcoming any partial inhibition caused by blockade of the other coreceptor.
The method of data presentation used in Table 2 means that 0 to 90% inhibition of a test virus by an inhibitor would be classed as negative. When the extent of inhibition is < 50%, such a categorization is probably reasonable, given the well-known limitations of the PBMC-based replication assay and its lack of precision in this range of inhibition. However, 85% inhibition, for example, does not necessarily indicate a lack of activity of a test compound against a test virus. We therefore analyzed the data sets in a different way, by calculating the mean degree of inhibition achieved by each concentration of each inhibitor and inhibitor-combination against all the isolates in each test panel ( Figs. 1-3 ). The error bars in these figures represent the standard deviation and illustrate the extensive biological variation among the isolates, not the degree of experimental error within the PBMC assay. Using more than one compound clearly increased the degree of inhibition of the R5 viruses in the test panel, more so when the inhibitor concentrations were low ( Fig. 1A ) than when they were 10-fold higher (Fig. 1B) . Similar results were observed in the experiments using the X4 virus test panel, particularly at the higher inhibitor concentrations (Fig.  2B) . At low, sub-optimal concentrations, none of the individual inhibitors was very effective against the R5X4 virus test panel, not even the tropism-independent compounds BMS-C and C52L. Combining AMD3465 with CMPD167 gave only ∼ 30% inhibition at these low concentrations, and combining BMS-C with C52L provided ∼ 40% inhibition. The combination of CoR = mixture of AMD3465 with CMPD167. a 0.1 nM for CMPD167 and 1 nM for all others, alone and in combinations. b 1 nM for CMPD167 and 10 nM for all others, alone and in combinations. c 100 nM for CMPD167 and 1 μM for all others, alone and in combinations. d 5 nM for AMD3465 and 1 nM for all others, alone and in combinations. e 50 nM for AMD3465 and 10 nM for all others, alone and in combinations. f 5 μM for AMD3465 and 1 μM for all others, alone and in combinations. At this high concentration of AMD3465, non-specific effects on some R5 virus infections were also seen. g 5 nM for AMD3465, 0.1 nM for CMPD167, and 1 nM for all others, alone and in combinations. h 50 nM for AMD3465, 1 nM for CMPD167, and 10 nM for all others, alone and in combinations. i 5 μM for AMD3465, 100 nM for CMPD167, and 1 μM for all others, alone and in combinations. At this high concentration of AMD3465 non-specific effects on R5 virus infection were also seen.
AMD3465, CMPD167 and BMS-C (or all four inhibitors together) did, however, improve the average inhibition to 55-60% (Fig. 3A) . Clear benefits of inhibitor combinations were apparent when the various compounds were tested against the R5X4 viruses at the 10-fold higher concentrations (Fig. 3B ). It should be noted that at higher, but still rather low, concentrations (50 nM and 1 nM), the combination of AMD3465 with CMPD167 was sufficient to completely inhibit infection by all the R5X4 viruses ( Fig. 3B and Table 2C ).
Pan-resistance and causes of weak inhibition
To assess whether there was any tendency to pan-resistance among the isolates, i.e. whether any isolates were insensitive to more than one inhibitor, we correlated the degree of inhibition caused by fixed concentrations of the individual compounds. These pair-wise correlations of single inhibitors against each other were always poor, r 2 < 0.16, which indicates that panresistance is rare among these test isolates for these inhibitors.
We also addressed whether the amount of viral replication could affect the extent to which the different viral stocks were susceptible to inhibition. We observed no such correlations for BMS-C, C52L or the coreceptor ligands within the whole set of isolates (r 2 < 0.25). We did, however, as an exception, observe a negative correlation between viral growth and AMD3465 inhibition in the X4 group (r 2 = 0.63, P = 0.0058). Hence differences in the extent of inhibition were for the most part not influenced by variations in the infectious viral dose used to initiate the replication assays for the different test viruses.
Finally, we addressed whether there was any difference in the sensitivity of the different isolates to the various inhibitors that was specific to any individual genetic subtype. First, we grouped the 44 R5, R5X4 and X4 isolates by subtypes. The degrees of inhibition by the coreceptor-independent inhibitors 
BMS-C and C52L
(1 nM, alone and in combination) were first compared. The degrees of inhibition among the different subtypes caused by CMPD167 (0.1 nM), in dual and triple combination with BMS-C and C52L (both at 1 nM), were then compared for the 25 R5 isolates. A Kruskal-Wallis test did not indicate that the median degrees of inhibition within the subtypes differed significantly in either case (P > 0.05). Hence, we conclude that the genetic subtype is not a strong determinant of sensitivity to the entry inhibitors we have studied here.
Discussion
HIV-1 global diversity is just as serious an issue in the development of an effective microbicide as it is for a vaccine. Clearly, a microbicide would be of limited value if it were only active against a small subset of the HIV-1 strains present in the geographic area where it was being used. In addition, adjusting the formulation of a microbicide to take account of the virus strains prevalent in different parts of the world (i.e., developing subtype-specific microbicides) would be undesirable, to say the least. Here, we have conducted an in vitro study of the activity of selected entry inhibitor microbicide candidates against HIV-1 isolates from different genetic subtypes. Our intent was to obtain baseline information on the extent to which HIV-1 sequence diversity could affect the performance of entry inhibitor-based microbicides, at least in vitro, and whether combinations could be useful in this regard. The particular inhibitors we chose are the ones we have studied, or are presently studying, in the macaque model, to determine their efficacy against vaginal challenge with SHIVs (Veazey et al., 2005; Veazey et al., unpublished results) . CMPD167 and BMS-C are presently being evaluated as clinical candidates by the International Partnership for Microbicides.
We report here that the activity of each of the selected inhibitors is substantially subtype-independent. In particular, the small-molecule CCR5 inhibitor CMPD167 and C52L, a gp41 peptide inhibitor of fusion, were almost pan-reactive against R5 viruses, and C52L was also active against X4 strains. CMPD167 was, as expected, inactive against X4 isolates. Conversely, the CXCR4 inhibitor AMD3465 was pan-reactive against X4 viruses, but inactive against R5 viruses. The gp120binding attachment inhibitor BMS-C was effective against most R5 and X4 viruses, although some were insensitive. Hence viewed solely from the perspective of their breadth of activity, these compounds are all suitable candidates for development as a microbicide component(s). Other factors, of course, will eventually determine whether any or all of them fulfill all the criteria necessary to create a useful product, including safety and the cost and practicality of manufacture and formulation .
We were not able to include enough test viruses from each of the major genetic subtypes to determine whether any particular subtype is more or less sensitive than average to the entry inhibitors. However, within the limitations of the panel size, there was no indication of any substantive, subtype-specific pattern to the actions of any of the compounds, which is consistent with earlier reports on other entry inhibitors (Cilliers et al., 2003; Trkola et al., 1998 Trkola et al., , 2001 and with the subtypeindependent nature of the HIV-1 fusion process (Gallo et al., 2003; Pope et al., 1997) . For entry inhibitors in general, any subtype-specific effects may be fairly subtle, at most. Likewise, the microbicide candidate CAP (cellulose acetate 1,2-benzene dicarboxylate), which interacts with positively charged residues in the Env glycoprotein, is active against viruses from multiple subtypes (Lu et al., 2006) .
There are obvious advantages to using several different inhibitors of HIV-1 entry in a combination microbicide, for essentially the same reason that a cocktail of inhibitors and not monotherapy is used to treat HIV-1 infection (Yeni et al., 2004) . In the context of the present study, one reason to use an inhibitor combination is that viruses resistant to one compound may still be sensitive to others. For example, 16% of the R5 test viruses were insensitive to BMS-C (< 90% inhibition at 1 μM), but all of the BMS-C-resistant viruses were inhibited by CMPD167 and/or C52L. No virus from among the 44 tested was insensitive to two of the different categories of inhibitor at the highest concentrations (0.1-5 μM excluding, of course, the expected ineffectiveness of the CCR5 inhibitor against X4 viruses and the CXCR4 inhibitor against R5 viruses). Thus in a combination of CMPD167, C52L and BMS-C, at least two of the inhibitors, and usually all three, were active against the R5 viruses in the test panel. Moreover, combining a CCR5 inhibitor with a CXCR4 inhibitor, or with coreceptor-independent inhibitors, is one solution to the problem of the rare transmissions of CXCR4-using viruses (Dhawan and Mayer, 2006; Lederman et al., 2006; Margolis and Shattock, 2006; .
All of the above conclusions are, of course, conditional on the concentrations of the test compounds, because their activities are dose-dependent and we used different concentrations in the nM to μM range in various experiments. In the macaque model, the inhibitors are applied at much higher, mM, concentrations when they provide protection against vaginal challenge with SHIV-162P3 (Veazey et al., 2005) . Although the local inhibitor concentrations at the site of virus deposition are not known, it seems unlikely that they will be as low as the nM range, at least initially . The local concentrations will dissipate with time, so eventually the lower, less active range will be reached. What inhibitor concentrations must be present within the vagina to protect women, and for how long, are not yet known, of course.
A second advantage of the use of inhibitor combinations is the potential for synergy; that is, the mutually reinforcing activity of two different compounds with complementary mechanisms of action. We did not, in this study, perform formal synergy analyses, but we have previously reported synergy between CMPD167 and both C52L and BMS-378806 against SHIV-162P3 replication in vitro (Veazey et al., 2005) . There are also several other reports of synergy between CCR5 inhibitors similar to CMPD167 and gp41 peptide fusion inhibitors similar to C52L (Tremblay et al., 2002 (Tremblay et al., , 2005a (Tremblay et al., ,2005b . In the context of a microbicide formulation for human use, synergy would act to reduce the amount of each inhibitor required to provide an effective blockade to HIV-1 transmission, a useful bonus to combination-based strategies.
There are two obvious limitations to this study: the choices of the test viruses and the target cells used in the infection inhibition assay. The viruses were almost all isolated from the peripheral blood of HIV-1-infected people, some relatively early in infection, others several years later. How precisely such viruses mimic those present in genital fluids that a microbicide must block from establishing a new infection remains to be determined, because such viruses are unavailable . The same considerations apply, of course, to the design of virus test panels for the evaluation of MAb-based HIV-1 vaccines (Binley et al., 2004; Brown et al., 2005; Li et al., 2005; Mascola et al., 2005; Rusert et al., 2005) . One possible approach is to use viruses isolated relatively early after HIV-1 infection of a new host, and we included such examples in our R5 test panel. However, viruses that expand in the host may differ phenotypically from those present in semen or vaginal fluids . Until test panels are assembled that include the latter categories of HIV-1 variants, it cannot be determined whether this issue is truly relevant. We suspect, however, that any such influence on microbicide efficacy in vitro will not be substantive enough to alter the broad conclusions we have drawn here.
The second principal limitation to this study is our use of PBMC as the target cell for HIV-1 replication. Given the scale of the study (44 test viruses and 4 inhibitors, alone and in combination) we had little choice but to work with PBMC. However, these cells are not the immediate target cells for sexual transmission of HIV-1 (Gupta and Klasse, 2006; Haase, 2005; Miller et al., 2005) . Thus, in principle, using PBMC could affect our conclusions, but again probably only to a minor extent. Firstly, several of the same compounds we have shown to be active against HIV-1 infection of PBMC also inhibit SHIV-162P3 vaginal transmission to macaques, so they must be active against whatever cells are infected early in the infection process (Veazey et al., 2005) . Secondly, the principal cell type in which HIV-1 replicates in activated PBMC is the CD4 + T-cell. Such cells are present at early sites of virus replication after vaginal transmission of SIVs or SHIVs, as are others such as the macrophage and dendritic cell (Gupta and Klasse, 2006; Haase, 2005; Hladik et al., 2007; Miller et al., 2005) . Small-molecule CCR5 inhibitors and gp41-based fusion peptides have previously been shown to inhibit HIV-1 infection of both these cell types in vitro, so we would not expect too much difference from our present results if we had used other cell types (Ketas et al., 2003a (Ketas et al., ,2003b Willey et al., 2005) . In broad terms, the mechanism of HIV-1 entry, and hence of its inhibition, is independent of the target cell in vitro (Gallo et al., 2003) . Nonetheless, it will be essential to also perform the present type of study using other in vitro experimental systems, such as cervical tissue explants and dendritic cells, to see whether any issues arise that are not visible in studies that use PBMC. Whether any in vitro system can always predict the activity of an inhibitor against virus transmission in vivo, in a model system or the real world, of course remains to be determined.
Using more than one entry inhibitor might also reduce the development of resistance (Olson and Maddon, 2003) . Most women in the developing world are unaware of their HIV-1 status, so it is probable that, outside a clinical trial setting, microbicides would be used by infected women. It is unclear whether any topical agent will cause resistant variants to evolve systemically, but inhibitor absorption into the body could result in sub-therapeutic levels that select for resistance, perhaps at local sites close to where the inhibitor is applied. This concern may apply to conventional antiviral drugs that are now being used widely for treating HIV-1 infection, something that does not yet apply to entry inhibitors. There is an argument that, in high-incidence areas like sub-Saharan Africa, entry inhibitors might best be reserved for the prevention of HIV-1 transmission, to avoid any possible impact of resistance development on the efficacy of therapy.
Overall, our results support the development of microbicide formulations based on the use of several different inhibitors of HIV-1 attachment and entry. If such a microbicide can be developed successfully, its efficacy may not be influenced too drastically by subtype-dependent HIV-1 sequence variation. We do not seek to trivialize the problem of HIV-1 sequence diversity, which is and will always remain formidable (McCutchan, 2006; Walker and Korber, 2001) . However, carefully chosen entry inhibitors, if used in combination, may be effective at blocking HIV-1 transmission irrespective of the viral subtype.
Methods
Entry inhibitors and MAbs
The small-molecule CCR5 inhibitor CMPD167 and the gp41-peptide fusion inhibitor C52L have been described previously, including evaluations of their activity against SHIV transmission to the rhesus macaque after vaginal administration (Veazey et al., 2005; Deng et al., 2007) . BMS-C is a more potent member of the same structural family of compounds as the gp120-binding attachment inhibitor BMS-378806 (Guo et al., 2003) . AMD3465 is a small-molecule inhibitor that binds to CXCR4 (Hatse et al., 2005) .
HIV-1 isolates
The isolates of defined coreceptor usage (R5, X4, R5X4) and genetic subtypes used in this study have all been described previously (see Table 1 ).
Preparation of PBMC and use in HIV-1 infection assay
Peripheral blood mononuclear cells (PBMC) were prepared from leukopacks obtained from the New York Blood Center (New York, NY). The PBMC were cultured in lymphocyte medium (LM) [RPMI 1640 supplemented with 10% fetal bovine serum (FBS), 2 mM L-glutamine (all media from Cellgro, Herndon, VA), and 100 U/ml IL-2 (NIH AIDS Research and Reference Reagent Program, contributed by Hoffman-LaRoche, Inc.)]. Equal parts of each PBMC culture were stimulated with either 5 μg/ml phytohemagglutinin (PHA; Sigma, St. Louis, MO) or with supernatant from the OKT3 hybridoma (anti-CD3 stimulation). After 3 days, an equal number of cells from the two different stimulation cultures were combined. PHA and OKT3 were removed by washing. Titration medium (TM, which is LM containing 100 μg/ml penicillin/ streptomycin) was added for the remainder of the culture period (Ketas et al., 2003b) . The PBMC were seeded at 100 μl per well into a 96-well plate (Becton Dickinson) at 1.4 × 10 6 cells/ml in TM before addition of a serially diluted inhibitor immediately prior to inoculation of the test virus (100 TCID 50 /well). The cultures were then continued with both virus and inhibitors present. HIV-1 replication was measured using an in-house p24 antigen ELISA on Day 7, then again on Day 10 or 14 if viral replication was insufficient. Residual p24 from the input virus was measured and subtracted in order to calculate total net p24 production (intracellular and extracellular) in the test wells.
Inhibition was expressed relative to p24 production in the control wells (no inhibitor, defined as 0% inhibition).
Statistical and mathematical analysis
The effect of the various inhibitors on the replication of a panel of HIV-1 test isolates in PBMC is presented in two different ways: (1) as the relative frequency of inhibition above a defined cut-off value; and (2) as the average degree of inhibition.
In the first method, the cut-off value for calculating the frequency of inhibition was selected to be 90% reduction of p24 production compared with control cultures (i.e., no inhibitor present). The rationale for this cut-off is that a 90% reduction in the infectivity of the inocula commonly used for experimental transmission of challenge viruses to macaques should provide significant protection from infection . Within each virus test panel, the number of isolates inhibited by > 90% is divided by the total number of isolates in the panel; the resulting relative frequency is presented as a percentage. The rationale here is that frequencies based on a high cut-off are likely to be the most important from the perspective of the practical development of an intervention strategy such as a microbicide. In other words, what proportion of the divergent viruses an inhibitor might encounter when used as a microbicide could it be expected to be effective against?
Because the above method of data presentation obscures any differences in partial inhibition that occur below the cut-off value (i.e., from 0 to 90% inhibition of p24 production), we also calculated the average degree of inhibition (± standard deviation) for all the isolates in each test panel. This strategy provides a complementary means of gauging the increase in inhibition resulting from combining two or more inhibitors. Biologically, this is relevant to the question: When the concentrations of individual inhibitors at mucosal sites fall below what is required for protection (e.g. in mucosal microenvironments, and over time), will their use in combinations still be able to counter the infectious inoculum?
In addition, to assess whether any test isolates were panresistant to all the relevant inhibitors (as opposed to being resistant to individual ones), we performed pair-wise correlations of the degree of inhibition by fixed concentrations of each inhibitor. Finally, to address whether variation in the extent to which different test isolates replicated caused the extent of inhibition by a test compound also to vary, we correlated the extent of inhibition with the amount of p24 produced in the absence of an inhibitor. These correlations were performed and the r 2 values were calculated using Prism (GraphPad). The justification for performing this analysis by correlations, rather than linear regression, is that only experimental variables, and no controlled parameters, were plotted against each other.
We addressed whether there was any genetic subtype-specific effect of the various inhibitors (alone and combined) by comparing the degrees of inhibition at fixed, intermediate concentrations, in a Kruskal-Wallis one-way analysis of variance by ranks. This non-parametric test was chosen because the sample numbers were sometimes too small to evaluate Gaussian distributions. When the Kruskal-Wallis test indicated that there were no overall discrepancies in rank sums among the groups (p > 0.05), Dunn's post-test was not done. All statistical analyses were performed in Prism (GraphPad).
